{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T15:37:07Z","timestamp":1788449827486,"version":"build-2803163510"},"reference-count":201,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2021,12,16]],"date-time":"2021-12-16T00:00:00Z","timestamp":1639612800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Perillyl alcohol (POH) is a naturally occurring monoterpenoid related to limonene that is present in the essential oils of various plants. It has diverse applications and can be found in household items, including foods, cosmetics, and cleaning supplies. Over the past three decades, it has also been investigated for its potential anticancer activity. Clinical trials with an oral POH formulation administered to cancer patients failed to realize therapeutic expectations, although an intra-nasal POH formulation yielded encouraging results in malignant glioma patients. Based on its amphipathic nature, POH revealed the ability to overcome biological barriers, primarily the blood\u2013brain barrier (BBB), but also the cytoplasmic membrane and the skin, which appear to be characteristics that critically contribute to POH\u2019s value for drug development and delivery. In this review, we present the physicochemical properties of POH that underlie its ability to overcome the obstacles placed by different types of biological barriers and consequently shape its multifaceted promise for cancer therapy and applications in drug development. We summarized and appraised the great variety of preclinical and clinical studies that investigated the use of POH for intranasal delivery and nose-to-brain drug transport, its intra-arterial delivery for BBB opening, and its permeation-enhancing function in hybrid molecules, where POH is combined with or conjugated to other therapeutic pharmacologic agents, yielding new chemical entities with novel mechanisms of action and applications.<\/jats:p>","DOI":"10.3390\/pharmaceutics13122167","type":"journal-article","created":{"date-parts":[[2021,12,16]],"date-time":"2021-12-16T21:32:40Z","timestamp":1639690360000},"page":"2167","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["The Monoterpenoid Perillyl Alcohol: Anticancer Agent and Medium to Overcome Biological Barriers"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2183-4667","authenticated-orcid":false,"given":"Thomas C.","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Neurological Surgery, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clovis O.","family":"da Fonseca","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, Federal Hospital of Ipanema, Rio de Janeiro 22411-020, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Levin","sequence":"additional","affiliation":[{"name":"Norac Pharma, Azusa, CA 91702, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0662-5653","authenticated-orcid":false,"given":"Axel H.","family":"Sch\u00f6nthal","sequence":"additional","affiliation":[{"name":"Department of Molecular Microbiology & Immunology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,12,16]]},"reference":[{"key":"ref_1","first-page":"193","article-title":"A Review of Blood\u2013Brain Barrier Transport Techniques","volume":"89","author":"Smith","year":"2003","journal-title":"Methods Mol. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1038\/nm.3407","article-title":"Development, maintenance and disruption of the blood-brain barrier","volume":"19","author":"Obermeier","year":"2013","journal-title":"Nat. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1146\/annurev-cellbio-100617-062608","article-title":"Development and Cell Biology of the Blood-Brain Barrier","volume":"35","author":"Langen","year":"2019","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1002\/ca.23083","article-title":"Blood brain barrier: A review of its anatomy and physiology in health and disease","volume":"31","author":"Sharif","year":"2018","journal-title":"Clin. Anat."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1038\/bjc.2012.163","article-title":"Incidence and time trends of brain metastases admissions among breast cancer patients in Sweden","volume":"106","author":"Frisk","year":"2012","journal-title":"Br. J. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1007\/s00432-018-2697-2","article-title":"Molecular subtype predicts incidence and prognosis of brain metastasis from breast cancer in SEER database","volume":"144","author":"Kim","year":"2018","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_7","first-page":"683730","article-title":"Targeting the Sanctuary Site: Options when Breast Cancer Metastasizes to the Brain","volume":"33","author":"Krishnan","year":"2019","journal-title":"Oncology"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Garcia-Alvarez, A., Papakonstantinou, A., and Oliveira, M. (2021). Brain Metastases in HER2-Positive Breast Cancer: Current and Novel Treatment Strategies. Cancers, 13.","DOI":"10.3390\/cancers13122927"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jocn.2019.04.028","article-title":"Survival trends in glioblastoma and association with treating facility volume","volume":"68","author":"Aulakh","year":"2019","journal-title":"J. Clin. Neurosci."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1007\/s00432-021-03596-5","article-title":"Patterns of glioblastoma treatment and survival over a 16-years period: Pooled data from the german cancer registries","volume":"147","author":"Efremov","year":"2021","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO Classification of Tumors of the Central Nervous System: A summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro-Oncology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1007\/s00520-020-05663-y","article-title":"Assessment of Karnofsky (KPS) and WHO (WHO-PS) performance scores in brain tumour patients: The role of clinician bias","volume":"29","author":"Frappaz","year":"2021","journal-title":"Support. Care Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","article-title":"Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial","volume":"10","author":"Stupp","year":"2009","journal-title":"Lancet Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2478\/raon-2018-0023","article-title":"Radiotherapy of glioblastoma 15 years after the landmark Stupp\u2019s trial: More controversies than standards?","volume":"52","author":"Kazda","year":"2018","journal-title":"Radiol. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3728","DOI":"10.1158\/1078-0432.CCR-03-0807","article-title":"Plasma and Cerebrospinal Fluid Population Pharmacokinetics of Temozolomide in Malignant Glioma Patients","volume":"10","author":"Ostermann","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"7092","DOI":"10.1158\/1078-0432.CCR-09-1349","article-title":"The Neuropharmacokinetics of Temozolomide in Patients with Resectable Brain Tumors: Potential Implications for the Current Approach to Chemoradiation","volume":"15","author":"Portnow","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"622615","DOI":"10.3389\/fphys.2021.622615","article-title":"The Normal and Brain Tumor Vasculature: Morphological and Functional Characteristics and Therapeutic Targeting","volume":"12","author":"Guyon","year":"2021","journal-title":"Front. Physiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1080\/10717544.2019.1616235","article-title":"A comprehensive review in improving delivery of small-molecule chemotherapeutic agents overcoming the blood-brain\/brain tumor barriers for glioblastoma treatment","volume":"26","author":"Wang","year":"2019","journal-title":"Drug Deliv."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1007\/s00432-012-1218-y","article-title":"Chemotherapy as primary treatment for brain metastases from breast cancer: Analysis of 115 one-year survivors","volume":"138","author":"Boogerd","year":"2012","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/(SICI)1097-0142(19990401)85:7<1599::AID-CNCR23>3.0.CO;2-#","article-title":"Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: A prospective study","volume":"85","author":"Franciosi","year":"1999","journal-title":"Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"5664","DOI":"10.1158\/1078-0432.CCR-10-1564","article-title":"Heterogeneous Blood\u2013Tumor Barrier Permeability Determines Drug Efficacy in Experimental Brain Metastases of Breast Cancer","volume":"16","author":"Lockman","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1093\/neuonc\/nox175","article-title":"Is the blood\u2013brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data","volume":"20","author":"Sarkaria","year":"2018","journal-title":"Neuro-Oncology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s11060-011-0564-y","article-title":"Tissue concentration of systemically administered antineoplastic agents in human brain tumors","volume":"104","author":"Pitz","year":"2011","journal-title":"J. Neuro-Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41568-019-0205-x","article-title":"The blood\u2013brain barrier and blood\u2013tumour barrier in brain tumours and metastases","volume":"20","author":"Arvanitis","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Marcucci, F., Corti, A., and Ferreri, A. (2021). Breaching the Blood\u2013Brain Tumor Barrier for Tumor Therapy. Cancers, 13.","DOI":"10.3390\/cancers13102391"},{"key":"ref_27","unstructured":"Wildman, R.E.C. (2001). Isoprenoids, health and disease. Neutraceuticals and Functional Foods, CRC Press."},{"key":"ref_28","first-page":"164","article-title":"Constituents of Essential Oils from Leaves, Stems, and Fruits of Perilla frutescens (L.) britt","volume":"17","author":"Pan","year":"1992","journal-title":"Zhongguo Zhong Yao Za Zhi"},{"key":"ref_29","first-page":"7","article-title":"Perillyl Alcohol (Monoterpene Alcohol), Limonene","volume":"36","author":"Shojaei","year":"2014","journal-title":"Struct. Funct. Regul. Tor Complexes Yeasts Mamm. Part B"},{"key":"ref_30","unstructured":"Kekul\u00e9, A. (1866). Lehrbuch der Organischen Chemie, Verlag von Ferdinand Enke."},{"key":"ref_31","unstructured":"Newman, A.A. (1972). Chemistry of Terpenes and Terpenoids, Academic Press."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Dion\u00edsio, A.P., Molina, G., de Carvalho, D.S., dos Santos, R., Bicas, J., and Pastore, G. (2012). Natural flavourings from biotechnology for foods and beverages. Natural Food Additives, Ingredients and Flavourings, Elsevier.","DOI":"10.1533\/9780857095725.1.231"},{"key":"ref_33","first-page":"455","article-title":"Evidence for the Difference between the Odours of the Optical Isomers (+)- and (\u2212)-Carvone","volume":"230","author":"Leitereg","year":"1971","journal-title":"Nat. Cell Biol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"14073","DOI":"10.1038\/srep14073","article-title":"Supersensitive detection and discrimination of enantiomers by dorsal olfactory receptors: Evidence for hierarchical odour coding","volume":"5","author":"Sato","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1351\/pac199668122193","article-title":"Basic terminology of stereochemistry (IUPAC Recommendations 1996)","volume":"68","author":"Moss","year":"1996","journal-title":"Pure Appl. Chem."},{"key":"ref_36","unstructured":"Chastain, D.E., Mody, N., and Majetich, G. (1999). Method of preparing perillyl alcohol and perillyl acetate. United. (US5994598), U.S. Patent."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ymben.2013.05.004","article-title":"Metabolic engineering of Escherichia coli for limonene and perillyl alcohol production","volume":"19","author":"Chan","year":"2013","journal-title":"Metab. Eng."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"107628","DOI":"10.1016\/j.biotechadv.2020.107628","article-title":"Microbial production of limonene and its derivatives: Achievements and perspectives","volume":"44","author":"Ren","year":"2020","journal-title":"Biotechnol. Adv."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Soares-Castro, P., Soares, F., and Santos, P.M. (2020). Current Advances in the Bacterial Toolbox for the Biotechnological Production of Monoterpene-Based Aroma Compounds. Molecules, 26.","DOI":"10.3390\/molecules26010091"},{"key":"ref_40","unstructured":"Chen, T., Levin, D., and Puppali, S. (2017). Pharmaceutical compositions comprising monoterpenes. United. (US9700524B2), U.S. Patent."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/BF00685549","article-title":"Identification of metabolites of the antitumor agent d-limonene capable of inhibiting protein isoprenylation and cell growth","volume":"31","author":"Crowell","year":"1992","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/0006-2952(94)90341-7","article-title":"Structure-activity relationships among monoterpene inhibitors of protein isoprenylation and cell proliferation","volume":"47","author":"Crowell","year":"1994","journal-title":"Biochem. Pharmacol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/BF00685658","article-title":"Mammary carcinoma regression induced by perillyl alcohol, a hydroxylated analog of limonene","volume":"34","author":"Haag","year":"1994","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1093\/carcin\/5.5.661","article-title":"Inhibition of DMBA-induced mammary cancer by the monoterpene d-limonene","volume":"5","author":"Elegbede","year":"1984","journal-title":"Carcinogenesis"},{"key":"ref_45","first-page":"323","article-title":"Regression of Rat Primary Mammary Tumors Following Dietary d-Limonene2","volume":"76","author":"Elegbede","year":"1986","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000224548","article-title":"Inhibition of Murine Subcutaneous and Intravenous Benzo(rst)pentaphene Carcinogenesis by Sweet Orange Oils and d-Limonene","volume":"25","author":"Homburger","year":"1971","journal-title":"Oncology"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/carcin\/12.1.115","article-title":"Inhibition of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone carcinogenesis in mice by D-limonene and citrus fruit oils","volume":"12","author":"Wattenberg","year":"1991","journal-title":"Carcinogenesis"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0304-3835(95)03747-K","article-title":"The inhibition of protein prenyltransferases by oxygenated metabolites of limonene and perillyl alcohol","volume":"91","author":"Gelb","year":"1995","journal-title":"Cancer Lett."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"17679","DOI":"10.1016\/S0021-9258(19)47425-5","article-title":"Selective inhibition of isoprenylation of 21-26-kDa proteins by the anticarcinogen d-limonene and its metabolites","volume":"266","author":"Crowell","year":"1991","journal-title":"J. Biol. Chem."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00005-008-0027-0","article-title":"Ras pathway activation in gliomas: A strategic target for intranasal administration of perillyl alcohol","volume":"56","author":"Linden","year":"2008","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/jcb.240590818","article-title":"Prevention and therapy of mammary cancer by monoterpenes","volume":"59","author":"Gould","year":"1995","journal-title":"J. Cell. Biochem."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1194\/jlr.M300057-JLR200","article-title":"Monoterpene regulation of Ras and Ras-related protein expression","volume":"44","author":"Holstein","year":"2003","journal-title":"J. Lipid Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1200\/JCO.1999.17.11.3631","article-title":"Ras Protein Farnesyltransferase: A Strategic Target for Anticancer Therapeutic Development","volume":"17","author":"Rowinsky","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0006-2952(97)00151-2","article-title":"Inhibition of type I and type II geranylgeranyl-protein transferases by the monoterpene perillyl alcohol in NIH3T3 cells","volume":"54","author":"Ren","year":"1997","journal-title":"Biochem. Pharmacol."},{"key":"ref_55","first-page":"1917","article-title":"Activation of the transforming growth factor beta signaling pathway and induction of cytostasis and apoptosis in mammary carcinomas treated with the anticancer agent perillyl alcohol","volume":"59","author":"Satomi","year":"1999","journal-title":"Cancer Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"779","DOI":"10.3892\/or.2012.2167","article-title":"Perillyl alcohol causes g1 arrest through p15(ink4b) and p21(waf1\/cip1) induction","volume":"29","author":"Koyama","year":"2013","journal-title":"Oncol. Rep."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1124\/jpet.106.111666","article-title":"Cell Cycle Arrest by the Isoprenoids Perillyl Alcohol, Geraniol, and Farnesol Is Mediated by p21Cip1and p27Kip1in Human Pancreatic Adenocarcinoma Cells","volume":"320","author":"Wiseman","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1023\/B:BREA.0000019966.97011.4d","article-title":"Perillyl Alcohol Inhibits Human Breast Cancer Cell Growth in vitro and in vivo","volume":"84","author":"Yuri","year":"2004","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1093\/carcin\/20.10.1957","article-title":"Induction of AP-1 activity by perillyl alcohol in breast cancer cells","volume":"20","author":"Satomi","year":"1999","journal-title":"Carcinogenesis"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1016\/j.biochi.2012.07.028","article-title":"The isoprenoid perillyl alcohol inhibits telomerase activity in prostate cancer cells","volume":"94","author":"Sundin","year":"2012","journal-title":"Biochimie"},{"key":"ref_61","first-page":"97","article-title":"Disruption of an htert-mtor-raptor protein complex by a phytochemical perillyl alcohol and rapamycin","volume":"375","author":"Sundin","year":"2013","journal-title":"Mol. Cell. Biochem."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.abb.2007.05.022","article-title":"Perillyl alcohol and genistein differentially regulate PKB\/Akt and 4E-BP1 phosphorylation as well as eIF4E\/eIF4G interactions in human tumor cells","volume":"465","author":"Peffley","year":"2007","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/j.yexcr.2013.05.029","article-title":"eIF4E-Overexpression imparts perillyl alcohol and rapamycin-mediated regulation of telomerase reverse transcriptase","volume":"319","author":"Sundin","year":"2013","journal-title":"Exp. Cell Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11010-010-0556-9","article-title":"The anticancer drug perillyl alcohol is a Na\/K-ATPase inhibitor","volume":"345","author":"Garcia","year":"2010","journal-title":"Mol. Cell. Biochem."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-015-0374-5","article-title":"Na\/K-ATPase as a target for anticancer drugs: Studies with perillyl alcohol","volume":"14","author":"Garcia","year":"2015","journal-title":"Mol. Cancer"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s11010-015-2593-x","article-title":"Inhibition of perillyl alcohol on cell invasion and migration depends on the Notch signaling pathway in hepatoma cells","volume":"411","author":"Ma","year":"2015","journal-title":"Mol. Cell. Biochem."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"8558","DOI":"10.1158\/0008-5472.CAN-04-4072","article-title":"Perillyl alcohol inhibits a calcium-dependent constitutive nuclear factor-kappab pathway","volume":"65","author":"Berchtold","year":"2005","journal-title":"Cancer Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.tox.2010.09.017","article-title":"Perillyl alcohol protects against ethanol induced acute liver injury in Wistar rats by inhibiting oxidative stress, NF\u03ba-B activation and proinflammatory cytokine production","volume":"279","author":"Khan","year":"2011","journal-title":"Toxicology"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ejphar.2014.09.015","article-title":"Perillyl alcohol improves functional and histological outcomes against ischemia-reperfusion injury by attenuation of oxidative stress and repression of cox-2, nos-2 and nf-kappab in middle cerebral artery occlusion rats","volume":"747","author":"Tabassum","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.intimp.2016.06.034","article-title":"Perillyl alcohol efficiently scavenges activity of cellular ROS and inhibits the translational expression of hypoxia-inducible factor-1\u03b1 via mTOR\/4E-BP1 signaling pathways","volume":"39","author":"Ma","year":"2016","journal-title":"Int. Immunopharmacol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1158\/1535-7163.MCT-12-0321","article-title":"Perillyl Alcohol for the Treatment of Temozolomide-Resistant Gliomas","volume":"11","author":"Cho","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1093\/jb\/mvr143","article-title":"CHOP is a multifunctional transcription factor in the ER stress response","volume":"151","author":"Nishitoh","year":"2012","journal-title":"J. Biochem."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1","DOI":"10.6064\/2012\/857516","article-title":"Endoplasmic Reticulum Stress: Its Role in Disease and Novel Prospects for Therapy","volume":"2012","year":"2012","journal-title":"Scientifica"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.bcp.2012.09.012","article-title":"Pharmacological targeting of endoplasmic reticulum stress signaling in cancer","volume":"85","year":"2013","journal-title":"Biochem. Pharmacol."},{"key":"ref_75","first-page":"1159","article-title":"Phase I clinical trial of perillyl alcohol administered daily","volume":"4","author":"Ripple","year":"1998","journal-title":"Clin. Cancer Res."},{"key":"ref_76","first-page":"390","article-title":"Phase I clinical and pharmacokinetic study of perillyl alcohol administered four times a day","volume":"6","author":"Ripple","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1006\/gyno.2002.6647","article-title":"A Phase II Trial of Daily Perillyl Alcohol in Patients with Advanced Ovarian Cancer: Eastern Cooperative Oncology Group Study E2E96","volume":"85","author":"Bailey","year":"2002","journal-title":"Gynecol. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1023\/A:1025437115182","article-title":"Phase II trial of perillyl alcohol (NSC 641066) administered daily in patients with metastatic androgen independent prostate cancer","volume":"21","author":"Liu","year":"2003","journal-title":"Investig. New Drugs"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s00280-007-0585-6","article-title":"Phase II trial of daily oral perillyl alcohol (NSC 641066) in treatment-refractory metastatic breast cancer","volume":"62","author":"Bailey","year":"2007","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.jss.2008.02.005","article-title":"A Pilot Study of Perillyl Alcohol in Pancreatic Cancer","volume":"147","author":"Matos","year":"2008","journal-title":"J. Surg. Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1385\/IJGC:32:2-3:125","article-title":"Phase II Trial of Perillyl Alcohol in Patients with Metastatic Colorectal Cancer","volume":"32","author":"Meadows","year":"2002","journal-title":"Int. J. Pancreatol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"100090","DOI":"10.1016\/j.phyplu.2021.100090","article-title":"Perillyl alcohol as a treatment for cancer: A systematic review","volume":"1","author":"Lima","year":"2021","journal-title":"Phytomedicine Plus"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.brainresbull.2018.10.009","article-title":"Evaluation of intranasal delivery route of drug administration for brain targeting","volume":"143","author":"Bors","year":"2018","journal-title":"Brain Res. Bull."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Keller, L.-A., Merkel, O., and Popp, A. (2021). Intranasal drug delivery: Opportunities and toxicologic challenges during drug development. Drug Deliv. Transl. Res., 1\u201323.","DOI":"10.1007\/s13346-020-00891-5"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1517\/17425247.2013.790887","article-title":"Direct nose to brain drug delivery via integrated nerve pathways bypassing the blood-brain barrier: An excellent platform for brain targeting","volume":"10","author":"Pardeshi","year":"2013","journal-title":"Epert Opin. Drug Deliv."},{"key":"ref_86","unstructured":"Pardeshi, C.V., and Souto, E.B. (2021). Direct transport theory: From the nose to the brain. Direct Nose-to-Brain Drug Delivery, Academic Press."},{"key":"ref_87","unstructured":"Pardeshi, C.V., and Souto, E.B. (2021). Basic considerations of anatomical and physiological aspects of the nose and the brain. Direct Nose-to-Brain Drug Delivery, Academic Press."},{"key":"ref_88","unstructured":"Pardeshi, C.V., and Souto, E.B. (2021). Physicochemical, biopharmaceutical, and practical considerations for efficient nose-to-brain drug delivery. Direct Nose-to-Brain Drug Delivery, Academic Press."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"G\u00e4nger, S., and Schindowski, K. (2018). Tailoring Formulations for Intranasal Nose-to-Brain Delivery: A Review on Architecture, Physico-Chemical Characteristics and Mucociliary Clearance of the Nasal Olfactory Mucosa. Pharmaceutics, 10.","DOI":"10.3390\/pharmaceutics10030116"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.lfs.2017.12.025","article-title":"Mechanism of intranasal drug delivery directly to the brain","volume":"195","author":"Crowe","year":"2018","journal-title":"Life Sci."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"709","DOI":"10.4155\/tde.14.41","article-title":"The nasal approach to delivering treatment for brain diseases: An anatomic, physiologic, and delivery technology overview","volume":"5","author":"Djupesland","year":"2014","journal-title":"Ther. Deliv."},{"key":"ref_92","first-page":"1580","article-title":"Preclinical development and clinical use of perillyl alcohol for chemoprevention and cancer therapy","volume":"5","author":"Chen","year":"2015","journal-title":"Am. J. Cancer Res."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.surneu.2006.02.034","article-title":"Anaplastic oligodendroglioma responding favorably to intranasal delivery of perillyl alcohol: A case report and literature review","volume":"66","author":"Masini","year":"2006","journal-title":"Surg. Neurol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.surneu.2007.07.040","article-title":"Preliminary results from a phase I\/II study of perillyl alcohol intranasal administration in adults with recurrent malignant gliomas","volume":"70","author":"Schwartsmann","year":"2008","journal-title":"Surg. Neurol."},{"key":"ref_95","first-page":"287","article-title":"Efficacy of monoterpene perillyl alcohol upon survival rate of patients with recurrent glioblastoma","volume":"137","author":"Lins","year":"2010","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_96","first-page":"5625","article-title":"Long-term outcome in patients with recurrent malignant glioma treated with Perillyl alcohol inhalation","volume":"33","author":"Teixeira","year":"2013","journal-title":"Anticancer Res."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"vdab005","DOI":"10.1093\/noajnl\/vdab005","article-title":"Phase I trial of intranasal NEO100, highly purified perillyl alcohol, in adult patients with recurrent glioblastoma","volume":"3","author":"Peereboom","year":"2021","journal-title":"Neuro-Oncol. Adv."},{"key":"ref_98","unstructured":"National Cancer Institute (2021, July 15). Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, Available online: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm#ctc_50."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1097\/00006123-199804000-00013","article-title":"Survival and functional status after resection of recurrent glioblastoma multiforme","volume":"42","author":"Barker","year":"1998","journal-title":"Neurosurgery"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1200\/JCO.2012.47.2464","article-title":"Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma","volume":"31","author":"Batchelor","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1093\/neuonc\/now035","article-title":"AVAREG: A phase II, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma","volume":"18","author":"Brandes","year":"2016","journal-title":"Neuro-Oncology"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"e114","DOI":"10.1002\/hsr2.114","article-title":"Single-institution retrospective review of patients with recurrent glioblastoma treated with bevacizumab in clinical practice","volume":"2","author":"Desjardins","year":"2019","journal-title":"Health Sci. Rep."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2217\/cns.15.8","article-title":"Use of bevacizumab in recurrent glioblastoma","volume":"4","author":"Ghiaseddin","year":"2015","journal-title":"CNS Oncol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"102029","DOI":"10.1016\/j.ctrv.2020.102029","article-title":"How did lomustine become standard of care in recurrent glioblastoma?","volume":"87","author":"Weller","year":"2020","journal-title":"Cancer Treat. Rev."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s10637-008-9215-3","article-title":"Correlation of tumor topography and peritumoral edema of recurrent malignant gliomas with therapeutic response to intranasal administration of perillyl alcohol","volume":"27","author":"Silva","year":"2009","journal-title":"Investig. New Drugs"},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Faria, G.M., Soares, I.D.P., D\u2019Alincourt Salazar, M., Amorim, M.R., Pessoa, B.L., da Fonseca, C.O., and Quirico-Santos, T. (2020). Intranasal perillyl alcohol therapy improves survival of patients with recurrent glioblastoma harboring mutant variant for mthfr rs1801133 polymorphism. BMC Cancer, 20.","DOI":"10.1186\/s12885-020-06802-8"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ccell.2018.04.011","article-title":"Biological Role and Therapeutic Potential of IDH Mutations in Cancer","volume":"34","author":"Waitkus","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"5562","DOI":"10.1158\/1078-0432.CCR-12-1773","article-title":"IDH1 and IDH2 Mutations in Tumorigenesis: Mechanistic Insights and Clinical Perspectives","volume":"18","author":"Yang","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1093\/carcin\/bgz134","article-title":"Friend or foe\u2014IDH1 mutations in glioma 10 years on","volume":"40","author":"Huang","year":"2019","journal-title":"Carcinogenesis"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/jjco\/hyaa162","article-title":"Survival in patients with glioblastoma at a first progression does not correlate with isocitrate dehydrogenase (IDH)1 gene mutation status","volume":"51","author":"Tabei","year":"2021","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"12","DOI":"10.7243\/2055-091X-2-12","article-title":"Perillyl alcohol inhalation concomitant with oral temozolomide halts progression of recurrent inoperable glioblastoma: A case report","volume":"2","author":"Soares","year":"2015","journal-title":"J. Histol. Histopathol."},{"key":"ref_112","first-page":"1263","article-title":"Efficacy of a ketogenic diet with concomitant intranasal perillyl alcohol as a novel strategy for the therapy of recurrent glioblastoma","volume":"15","author":"Santos","year":"2017","journal-title":"Oncol. Lett."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"389","DOI":"10.25259\/SNI_445_2020","article-title":"Adjuvant effect of low-carbohydrate diet on outcomes of patients with recurrent glioblastoma under intranasal perillyl alcohol therapy","volume":"11","author":"Santos","year":"2020","journal-title":"Surg. Neurol. Int."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0378-4347(99)00065-1","article-title":"Gas chromatographic\u2013mass spectrometric analysis of perillyl alcohol and metabolites in plasma","volume":"728","author":"Zhang","year":"1999","journal-title":"J. Chromatogr. B Biomed. Sci. Appl."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"e5037","DOI":"10.1002\/bmc.5037","article-title":"Intranasal administration of perillyl alcohol\u2013loaded nanoemulsion and pharmacokinetic study of its metabolite perillic acid in plasma and brain of rats using ultra-performance liquid chromatography\/tandem mass spectrometry","volume":"35","author":"Santos","year":"2021","journal-title":"Biomed. Chromatogr."},{"key":"ref_116","first-page":"268","article-title":"Simultaneous measurement of perillyl alcohol and its metabolite perillic acid in plasma and lung after inhalational administration in Wistar rats","volume":"12","author":"Rodrigues","year":"2019","journal-title":"Drug Test. Anal."},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Marin, A.A., Murillo, O., Sussmann, R.A., Ortolan, L.S., Battagello, D.S., Quirino, T.D.C., Bittencourt, J.C., Epiphanio, S., Katzin, A.M., and Carvalho, L.J.M. (2021). Perillyl Alcohol Reduces Parasite Sequestration and Cerebrovascular Dysfunction during Experimental Cerebral Malaria. Antimicrob. Agents Chemother., 65.","DOI":"10.1128\/AAC.00004-21"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-021-85293-4","article-title":"Intranasal administration of the chemotherapeutic perillyl alcohol results in selective delivery to the cerebrospinal fluid in rats","volume":"11","author":"Nehra","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"90","DOI":"10.2174\/2211738507666190321112237","article-title":"Co-Delivery Nanosystems for Cancer Treatment: A Review","volume":"7","author":"Eftekhari","year":"2019","journal-title":"Pharm. Nanotechnol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1080\/17425247.2020.1739647","article-title":"Co-delivery system of chemotherapy drugs and active ingredients from natural plants: A brief overview of preclinical research for cancer treatment","volume":"17","author":"Guo","year":"2020","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"120714","DOI":"10.1016\/j.ijpharm.2021.120714","article-title":"Nose-to-brain co-delivery of drugs for glioblastoma treatment using nanostructured system","volume":"603","author":"Ferreira","year":"2021","journal-title":"Int. J. Pharm."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"112905","DOI":"10.1016\/j.ejmech.2020.112905","article-title":"Non-invasive intranasal administration route directly to the brain using dendrimer nanoplatforms: An opportunity to develop new CNS drugs","volume":"209","author":"Mignani","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"959","DOI":"10.3171\/2018.11.JNS181161","article-title":"Efficient brain targeting and therapeutic intracranial activity of bortezomib through intranasal co-delivery with NEO100 in rodent glioblastoma models","volume":"132","author":"Wang","year":"2020","journal-title":"J. Neurosurg."},{"key":"ref_124","first-page":"CD010816","article-title":"Bortezomib for the treatment of multiple myeloma","volume":"4","author":"Scott","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s00280-007-0424-9","article-title":"Tissue distribution and depletion kinetics of bortezomib and bortezomib-related radioactivity in male rats after single and repeated intravenous injection of 14C-bortezomib","volume":"60","author":"Hemeryck","year":"2007","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_126","first-page":"1283","article-title":"Proteasome inhibition by bortezomib does not translate into efficacy on two malignant glioma xenografts","volume":"20","author":"Pinel","year":"1994","journal-title":"Oncol. Rep."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"695","DOI":"10.3171\/2016.11.JNS161212","article-title":"Intratumoral delivery of bortezomib: Impact on survival in an intracranial glioma tumor model","volume":"128","author":"Wang","year":"2018","journal-title":"J. Neurosurg."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/neuonc\/nor198","article-title":"Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: A north central cancer treatment group study","volume":"14","author":"Friday","year":"2011","journal-title":"Neuro-Oncology"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s11060-015-1894-y","article-title":"A phase II trial of tamoxifen and bortezomib in patients with recurrent malignant gliomas","volume":"125","author":"Odia","year":"2015","journal-title":"J. Neuro-Oncol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s11060-016-2156-3","article-title":"A phase II trial evaluating the effects and intra-tumoral penetration of bortezomib in patients with recurrent malignant gliomas","volume":"129","author":"Raizer","year":"2016","journal-title":"J. Neuro-Oncol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.3171\/2013.7.JNS1323","article-title":"Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells\u2019 VEGF production and angiogenesis","volume":"119","author":"Bota","year":"2013","journal-title":"J. Neurosurg."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1158\/0008-5472.CAN-07-5555","article-title":"Aggravated Endoplasmic Reticulum Stress as a Basis for Enhanced Glioblastoma Cell Killing by Bortezomib in Combination with Celecoxib or Its Non-Coxib Analogue, 2,5-Dimethyl-Celecoxib","volume":"68","author":"Kardosh","year":"2008","journal-title":"Cancer Res."},{"key":"ref_133","first-page":"4499","article-title":"Activity of bortezomib in glioblastoma","volume":"26","author":"Styczynski","year":"2007","journal-title":"Anticancer. Res."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11060-010-0466-4","article-title":"Inconsistent blood brain barrier disruption by intraarterial mannitol in rabbits: Implications for chemotherapy","volume":"104","author":"Joshi","year":"2010","journal-title":"J. Neuro-Oncol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1097\/ALN.0b013e318182c81b","article-title":"Intracarotid delivery of drugs: The potential and the pitfalls","volume":"109","author":"Joshi","year":"2008","journal-title":"Anesthesiology"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3109\/02841868209134015","article-title":"Permeability of the Blood-Brain Barrier in the Rat after Local Proton Irradiation","volume":"21","author":"Lundqvist","year":"1982","journal-title":"Acta Radiol. Oncol."},{"key":"ref_137","first-page":"321","article-title":"Radiation-induced apoptosis of endothelial cells in the murine central nervous system: Protection by fibroblast growth factor and sphingomyelinase deficiency","volume":"60","author":"Fuks","year":"2000","journal-title":"Cancer Res."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.trecan.2019.06.003","article-title":"Improving CNS Delivery to Brain Metastases by Blood\u2013Tumor Barrier Disruption","volume":"5","author":"Sprowls","year":"2019","journal-title":"Trends Cancer"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ddtec.2016.07.007","article-title":"Ultrasound-mediated drug delivery to the brain: Principles, progress and prospects","volume":"20","author":"Dasgupta","year":"2016","journal-title":"Drug Discov. Today Technol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-019-12426-9","article-title":"First-in-human trial of blood\u2013brain barrier opening in amyotrophic lateral sclerosis using MR-guided focused ultrasound","volume":"10","author":"Abrahao","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"343re2","DOI":"10.1126\/scitranslmed.aaf6086","article-title":"Clinical trial of blood-brain barrier disruption by pulsed ultrasound","volume":"8","author":"Carpentier","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"E8717","DOI":"10.1073\/pnas.1807105115","article-title":"Mechanisms of enhanced drug delivery in brain metastases with focused ultrasound-induced blood\u2013tumor barrier disruption","volume":"115","author":"Arvanitis","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_143","doi-asserted-by":"crossref","unstructured":"Wang, W., He, H., Mar\u00edn-Ramos, N.I., Zeng, S., Swenson, S., Cho, H.-Y., Fu, J., Beringer, P.M., Neman, J., and Chen, L. (2021). Enhanced brain delivery and therapeutic activity of trastuzumab after blood-brain barrier opening by neo100 in mouse models of brain-metastatic breast cancer. Neuro Oncol., e-pub ahead of print.","DOI":"10.1093\/neuonc\/noab041"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1093\/neuonc\/noaa206","article-title":"NEO100 enables brain delivery of blood\u2013brain barrier impermeable therapeutics","volume":"23","author":"Wang","year":"2021","journal-title":"Neuro-Oncology"},{"key":"ref_145","first-page":"CD011364","article-title":"Ultrasound-guided arterial cannulation for paediatrics","volume":"9","author":"Raphael","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1177\/021849230601400109","article-title":"Femoral Artery Cannulation in Stanford Type a Aortic Dissection Operations","volume":"14","author":"Hou","year":"2006","journal-title":"Asian Cardiovasc. Thorac. Ann."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1177\/0267659115588631","article-title":"Femoral cannulation: A safe vascular access option for cardiopulmonary bypass in minimally invasive cardiac surgery","volume":"31","author":"Saadat","year":"2016","journal-title":"Perfusion"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1161\/CIRCULATIONAHA.111.032235","article-title":"Femoral Arterial Access and Closure","volume":"124","author":"Bangalore","year":"2011","journal-title":"Circulation"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/cc1489","article-title":"Clinical review: Complications and risk factors of peripheral arterial catheters used for haemodynamic monitoring in anaesthesia and intensive care medicine","volume":"6","author":"Scheer","year":"2002","journal-title":"Crit. Care"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/j.athoracsur.2004.04.072","article-title":"Femoral Cannulation is Safe for Type A Dissection Repair","volume":"78","author":"Fusco","year":"2004","journal-title":"Ann. Thorac. Surg."},{"key":"ref_151","unstructured":"Grotta, J.C. (2016). Cerebral angiography. Stroke: Pathophysiology, Diagnosis, and Management, Elsevier Inc.. [6th ed.]."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1039\/c1np00045d","article-title":"Enzymatic methods for glyco(diversification\/randomization) of drugs and small molecules","volume":"28","author":"Gantt","year":"2011","journal-title":"Nat. Prod. Rep."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1248\/cpb.43.920","article-title":"Inhibitory Effect of Perillosides A and C, and Related Monoterpene Glucosides on Aldose Reductase and Their Structure-Activity Relationships","volume":"43","author":"Fujita","year":"1995","journal-title":"Chem. Pharm. Bull."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/s10637-009-9248-2","article-title":"Possible contribution of beta-glycosidases and caspases in the cytotoxicity of novel glycoconjugates in colon cancer cells","volume":"28","author":"Arafa","year":"2010","journal-title":"Invest New Drugs"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"7478","DOI":"10.1021\/jm500870u","article-title":"The Identification of Perillyl Alcohol Glycosides with Improved Antiproliferative Activity","volume":"57","author":"Nandurkar","year":"2014","journal-title":"J. Med. Chem."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1080\/10242420902811089","article-title":"Enzymatic synthesis of perillyl alcohol derivatives and investigation of their antiproliferative activity","volume":"27","author":"Xanthakis","year":"2009","journal-title":"Biocatal. Biotransformation"},{"key":"ref_157","doi-asserted-by":"crossref","unstructured":"Said, B., Montenegro, I., Valenzuela, M., Olgu\u00edn, Y., Caro, N., Werner, E., Godoy, P., Villena, J., and Madrid, A. (2018). Synthesis and Antiproliferative Activity of New Cyclodiprenyl Phenols against Select Cancer Cell Lines. Molecules, 23.","DOI":"10.3390\/molecules23092323"},{"key":"ref_158","doi-asserted-by":"crossref","unstructured":"Rezende, A.A., Santos, R.S., Andrade, L.N., Amaral, R.G., Pereira, M.M., Bani, C., Chen, M., Priefer, R., da Silva, C.F., and de Albuquerque Junior, R.L.C. (2021). Anti-tumor efficiency of perillylalcohol\/beta-cyclodextrin inclusion complexes in a sarcoma s180-induced mice model. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13020245"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.2174\/1389557521666210212150504","article-title":"Limonene and perillyl alcohol derivatives: Synthesis and anticancer activity","volume":"21","author":"Gosmann","year":"2021","journal-title":"Mini Rev. Med. Chem."},{"key":"ref_160","doi-asserted-by":"crossref","unstructured":"Zieli\u0144ska-B\u0142ajet, M., Pietrusiak, P., and Feder-Kubis, J. (2021). Selected Monocyclic Monoterpenes and Their Derivatives as Effective Anticancer Therapeutic Agents. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22094763"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nchembio.118","article-title":"Network pharmacology: The next paradigm in drug discovery","volume":"4","author":"Hopkins","year":"2008","journal-title":"Nat. Chem. Biol."},{"key":"ref_162","doi-asserted-by":"crossref","unstructured":"Szumilak, M., Wiktorowska-Owczarek, A., and Stanczak, A. (2021). Hybrid Drugs\u2014A Strategy for Overcoming Anticancer Drug Resistance?. Molecules, 26.","DOI":"10.3390\/molecules26092601"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1039\/C8MD00270C","article-title":"Synthesis of novel perillyl-dihydropyrimidinone hybrids designed for antiproliferative activity","volume":"9","author":"Vendrusculo","year":"2018","journal-title":"Medchemcomm"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s11030-017-9806-z","article-title":"Recent developments in the synthesis and applications of dihydropyrimidin-2(1H)-ones and thiones","volume":"22","author":"Mohammadi","year":"2018","journal-title":"Mol. Divers."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1158\/1535-7163.MCT-13-0882","article-title":"A Novel Temozolomide\u2013Perillyl Alcohol Conjugate Exhibits Superior Activity against Breast Cancer Cells In Vitro and Intracranial Triple-Negative Tumor Growth In Vivo","volume":"13","author":"Chen","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12929-015-0175-6","article-title":"Chemotherapeutic effect of a novel temozolomide analog on nasopharyngeal carcinoma in vitro and in vivo","volume":"22","author":"Chen","year":"2015","journal-title":"J. Biomed. Sci."},{"key":"ref_167","doi-asserted-by":"crossref","unstructured":"Sch\u00f6nthal, A., Swenson, S., Minea, R., Kim, H., Cho, H., Mohseni, N., Kim, Y.-M., and Chen, T. (2021). Potentially Curative Therapeutic Activity of NEO212, a Perillyl Alcohol-Temozolomide Conjugate, in Preclinical Cytarabine-Resistant Models of Acute Myeloid Leukemia. Cancers, 13.","DOI":"10.3390\/cancers13143385"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.canlet.2014.12.021","article-title":"A novel temozolomide analog, NEO212, with enhanced activity against MGMT-positive melanoma in vitro and in vivo","volume":"358","author":"Chen","year":"2015","journal-title":"Cancer Lett."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"vdaa160","DOI":"10.1093\/noajnl\/vdaa160","article-title":"Pharmacokinetic properties of the temozolomide perillyl alcohol conjugate (NEO212) in mice","volume":"2","author":"Cho","year":"2020","journal-title":"Neuro-Oncol. Adv."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1158\/1535-7163.MCT-13-0964","article-title":"NEO212, Temozolomide Conjugated to Perillyl Alcohol, Is a Novel Drug for Effective Treatment of a Broad Range of Temozolomide-Resistant Gliomas","volume":"13","author":"Cho","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.canlet.2015.11.040","article-title":"A novel drug conjugate, NEO212, targeting proneural and mesenchymal subtypes of patient-derived glioma cancer stem cells","volume":"371","author":"Jhaveri","year":"2016","journal-title":"Cancer Lett."},{"key":"ref_172","doi-asserted-by":"crossref","unstructured":"Di Francia, R., Crisci, S., De Monaco, A., Cafiero, C., Re, A., Iaccarino, G., De Filippi, R., Frigeri, F., Corazzelli, G., and Micera, A. (2021). Response and Toxicity to Cytarabine Therapy in Leukemia and Lymphoma: From Dose Puzzle to Pharmacogenomic Biomarkers. Cancers, 13.","DOI":"10.3390\/cancers13050966"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"102","DOI":"10.2174\/1874467211205010102","article-title":"Temozolomide: Mechanisms of action, repair and resistance","volume":"5","author":"Zhang","year":"2012","journal-title":"Curr. Mol. Pharmacol."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1527-3458.2001.tb00206.x","article-title":"The Antidepressant and Antiinflammatory Effects of Rolipram in the Central Nervous System","volume":"7","author":"Zhu","year":"2001","journal-title":"CNS Drug Rev."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"268","DOI":"10.4161\/cbt.80","article-title":"The type iv phosphodiesterase inhibitor rolipram induces expression of the cell cycle inhibitors p21(cip1) and p27(kip1), resulting in growth inhibition, increased differentiation, and subsequent apoptosis of malignant a-172 glioma cells","volume":"1","author":"Chen","year":"2002","journal-title":"Cancer Biol. Ther."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"7717","DOI":"10.1158\/1078-0432.CCR-08-0827","article-title":"Targeted Inhibition of Cyclic AMP Phosphodiesterase-4 Promotes Brain Tumor Regression","volume":"14","author":"Goldhoff","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1158\/1535-7163.MCT-18-0465","article-title":"The Rolipram\u2013Perillyl Alcohol Conjugate (NEO214) Is A Mediator of Cell Death through the Death Receptor Pathway","volume":"18","author":"Cho","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"ref_178","doi-asserted-by":"crossref","unstructured":"Chen, T.C., Chan, N., Labib, S., Yu, J., Cho, H.-Y., Hofman, F.M., and Sch\u00f6nthal, A.H. (2018). Induction of Pro-Apoptotic Endoplasmic Reticulum Stress in Multiple Myeloma Cells by NEO214, Perillyl Alcohol Conjugated to Rolipram. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19010277"},{"key":"ref_179","doi-asserted-by":"crossref","unstructured":"Fan, T., Sun, G., Sun, X., Zhao, L., Zhong, R., and Peng, Y. (2019). Tumor Energy Metabolism and Potential of 3-Bromopyruvate as an Inhibitor of Aerobic Glycolysis: Implications in Tumor Treatment. Cancers, 11.","DOI":"10.3390\/cancers11030317"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/ng.2471","article-title":"MCT1-mediated transport of a toxic molecule is an effective strategy for targeting glycolytic tumors","volume":"45","author":"Birsoy","year":"2013","journal-title":"Nat. Genet."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.canlet.2017.04.015","article-title":"A perillyl alcohol-conjugated analog of 3-bromopyruvate without cellular uptake dependency on monocarboxylate transporter 1 and with activity in 3-BP-resistant tumor cells","volume":"400","author":"Chen","year":"2017","journal-title":"Cancer Lett."},{"key":"ref_182","first-page":"S91","article-title":"Valproic acid: An old drug newly discovered as inhibitor of histone deacetylases","volume":"83","year":"2004","journal-title":"Ann. Hematol."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"109475","DOI":"10.1016\/j.celrep.2021.109475","article-title":"Medulloblastoma uses GABA transaminase to survive in the cerebrospinal fluid microenvironment and promote leptomeningeal dissemination","volume":"36","author":"Martirosian","year":"2021","journal-title":"Cell Rep."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"169","DOI":"10.15171\/apb.2018.021","article-title":"Chemical Enhancer: A Simplistic Way to Modulate Barrier Function of the Stratum Corneum","volume":"8","author":"Haque","year":"2018","journal-title":"Adv. Pharm. Bull."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s00403-018-1841-9","article-title":"Stratum corneum substantivity: Drug development implications","volume":"310","author":"Li","year":"2018","journal-title":"Arch. Dermatol. Res."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1080\/17425247.2020.1713087","article-title":"Permeation enhancers in transdermal drug delivery: Benefits and limitations","volume":"17","year":"2020","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.4155\/tde.15.61","article-title":"Chemical penetration enhancers","volume":"6","author":"Lopes","year":"2015","journal-title":"Ther. Deliv."},{"key":"ref_188","doi-asserted-by":"crossref","unstructured":"Chen, J., Jiang, Q.-D., Chai, Y.-P., Zhang, H., Peng, P., and Yang, X.-X. (2016). Natural Terpenes as Penetration Enhancers for Transdermal Drug Delivery. Molecules, 21.","DOI":"10.3390\/molecules21121709"},{"key":"ref_189","first-page":"1","article-title":"Esters of terpene alcohols as highly potent, reversible, and low toxic skin penetration enhancers","volume":"9","author":"Paraskevopoulos","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_190","first-page":"573","article-title":"Effects of perillyl alcohol on melanoma in the TPras mouse model","volume":"11","author":"Morreale","year":"2002","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.cbi.2008.12.016","article-title":"Perillyl alcohol attenuates Ras-ERK signaling to inhibit murine skin inflammation and tumorigenesis","volume":"179","author":"Chaudhary","year":"2009","journal-title":"Chem.-Biol. Interact."},{"key":"ref_192","first-page":"711","article-title":"Inhibitory effects of perillyl alcohol on UVB-induced murine skin cancer and AP-1 transactivation","volume":"58","author":"Barthelman","year":"1998","journal-title":"Cancer Res."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.ijpharm.2003.09.026","article-title":"Development of a perillyl alcohol topical cream formulation","volume":"269","author":"Gupta","year":"2004","journal-title":"Int. J. Pharm."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1080\/01635580701840391","article-title":"Phase 1 Study of Topical Perillyl Alcohol Cream for Chemoprevention of Skin Cancer","volume":"60","author":"Stratton","year":"2008","journal-title":"Nutr. Cancer"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1158\/1940-6207.CAPR-09-0183","article-title":"A Phase 2a Study of Topical Perillyl Alcohol Cream for Chemoprevention of Skin Cancer","volume":"3","author":"Stratton","year":"2010","journal-title":"Cancer Prev. Res."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2174\/18715230113126660021","article-title":"Skin Repair Properties of d-Limonene and Perillyl Alcohol in Murine Models","volume":"13","author":"Mirshahi","year":"2014","journal-title":"Anti-Inflamm. Anti-Allergy Agents Med. Chem."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"106766","DOI":"10.1016\/j.intimp.2020.106766","article-title":"Limonene, a food additive, and its active metabolite perillyl alcohol improve regeneration and attenuate neuropathic pain after peripheral nerve injury: Evidence for il-1beta, tnf-alpha, gap, ngf and erk involvement","volume":"86","author":"Pereira","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/j.1365-4632.2010.04423.x","article-title":"Treatment options in melanoma in situ: Topical and radiation therapy, excision and Mohs surgery","volume":"49","author":"Erickson","year":"2010","journal-title":"Int. J. Dermatol."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.xphs.2015.11.032","article-title":"Essential Fatty Acids as Transdermal Penetration Enhancers","volume":"105","author":"Gerber","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.3109\/03639045.2015.1047847","article-title":"Penetration enhancing effects of selected natural oils utilized in topical dosage forms","volume":"41","author":"Viljoen","year":"2015","journal-title":"Drug Dev. Ind. Pharm."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"37026","DOI":"10.18632\/oncotarget.26443","article-title":"NEO412: A temozolomide analog with transdermal activity in melanoma in vitro and in vivo","volume":"9","author":"Swenson","year":"2018","journal-title":"Oncotarget"}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/13\/12\/2167\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:49:20Z","timestamp":1760168960000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/13\/12\/2167"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,16]]},"references-count":201,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["pharmaceutics13122167"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics13122167","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,16]]}}}